

CURRICULUM VITAE
MICHAEL D. ISEMAN, M.D.

I. Present Position: Professor of Medicine
Division of Respiratory and Infectious Diseases
National Jewish Health

Rank: Professor of Medicine
University of Colorado School of Medicine

II. Educational History:

1957-1961 B.A., Cum Laude, History
Princeton University
Princeton, New Jersey

1961-1965 M.D., 1965
Columbia University
College of Physicians & Surgeons
New York, New York

Postgraduate Training:

1965-1967 Internship and Junior Residency in Medicine
Columbia Service, Bellevue Hospital
New York, New York

1967-1969 Military Service, U.S. Navy
Pearl Harbor, Hawaii

1969-1970 Senior Residency in Medicine
Columbia Service, Harlem Hospital
New York, New York

1970-1972 Fellowship in Pulmonary Medicine
Columbia Service, Harlem Hospital
New York, New York

Board Certification:

1972 American Board of Internal Medicine, Certified
1976 Pulmonary Medicine, Board Certified

III. Professional Positions:

Previous Positions

1971-1972	Assistant in Medicine Columbia College of Physicians and Surgeons New York, New York
1972-1973	Instructor in Medicine University of Colorado School of Medicine Denver, Colorado
1972-1982	Associate Director, Pulmonary Service Denver General Hospital Denver, Colorado
1973-1979	Assistant Professor of Medicine University of Colorado School of Medicine Denver, Colorado
1974-1975	Acting Director Eastside Neighborhood Health Center Denver, Colorado
1976-1980	Director, Denver Metro Tuberculosis Clinic Denver, Colorado
1979-1989	Associate Professor of Medicine University of Colorado School of Medicine Denver, Colorado
1989 -present	Professor of Medicine University of Colorado School of Medicine Denver, Colorado
1982-2004	Chief, Clinical Mycobacteriology Service Department of Medicine (The Girard & Madeline Beno Chair in Mycobacterial Diseases) National Jewish Medical and Research Center Denver, Colorado

IV. Honors and Awards:

1980 and 1981	Recipient of the Kaiser Permanente Award for "Excellence in Teaching" University of Colorado School of Medicine
---------------	---

- 1995 Recipient, "Medal for Excellence in Clinical Medicine"
Alumni Association, Columbia University
College of Physician's & Surgeons
- 1996 Lecture, "Louis E. Guerrero Memorial "
University of Santa Tomas
Manila, Philippines
- 1997 Inductee, Pulmonary Hall of Fame
Colorado Trudeau Society
American Lung Association of Colorado
- 1999 Louis B. Mark Memorial Lecture
American College Of Chest Physicians
Chicago, Illinois
- 2001 The James D. Bruce Public Health Award,
The American College of Physicians
Atlanta, Georgia
- 2005 Edward Livingston Trudeau Medal
American Thoracic Society
- 2006 Honorary Member of Mexican Thoracic Society
- 2006 F. Murray Konrfield Award
American College of Chest Physicians
Salt Lake City, Utah
- 2007 Robert W. Schrier MD Award of Excellence
Department of Medicine
University of Colorado School of Medicine
Denver, CO

V. Professional Affiliations: (Current)

Fellow, American College of Physicians
Fellow, American College of Chest Physicians
American Thoracic Society
Colorado Trudeau Society
American Lung Association of Colorado
President, American Society for Tuberculosis Education & Research (ASTER)

VI. Professional Service and Committees:**A. Institutional and Departmental Committees:**

1975-1978	Member, Admissions Committee, University of Colorado
1979-1982	School of Medicine.
1981-1984	Co-Director, Residency Program, Department of Medicine, University of Colorado School of Medicine.
1981-1997	Member, Intern Selection Committee, Department of Medicine, University of Colorado School of Medicine.
1983-present	Course Director, "Clinical Management and Control of Tuberculosis," National Jewish Medical and Research Center.
1984-present	Member, Faculty Promotions Committee, University of Colorado School of Medicine.
1990-1992	Member, Faculty Senate, University of Colorado School of Medicine.
1991-1995	Member, Clinical Investigation Committee, National Jewish Medical and Research Center
1995-1998	Medical Executive Committee, National Jewish Medical and Research Center

B. International Service:

1999-present	Member, World Health Organization, Working Group on DOTS-PLUS for MDR-TB, Geneva Switzerland.
--------------	---

C. National Service:

1979-1980	Chairman, Scientific Assembly on Tuberculosis of the American Thoracic Society
1980-1981	Chairman, Section on Tuberculosis, Forum on Infection and Immunology, American College of Chest Physicians
1983-1984	Vice-President, American Thoracic Society
1990-1993	Member, The Advisory Council for the Elimination of Tuberculosis, Centers for Disease Control and Prevention, United States Public Health Service

- 1991-1994 Delegate, American Thoracic Society Council of Chapter Representatives,
- 1992 Member, Planning Committee, World Congress on Tuberculosis, November, 1992, Bethesda, Maryland
- 1993-1997 Member, National Advisory Committee, Robert Wood Johnson Foundation's Program, "Old Disease, New Challenge: Tuberculosis in the 1990's"
- 1998-2000 Member, Advisory Committee on Tuberculosis, Soros' Open Society Institute.
- 1999-present Member, American Thoracic Society/CDC Committee to Revise Guidelines (1994) on the Treatment and Prevention of Tuberculosis.

D. Local and Community:

- 1978-1979 President, Colorado Trudeau Society
- 1982-1983 President, American Lung Association of Colorado
- 1978-1979 President, Medical Staff, Denver Department of Health and Hospitals
1985-1986
- 1977-present Member, Rocky Mountain Alumni Schools Committee, Princeton University,
- 1981-1985 Trustee, Princeton University
- 1985-1993 Member, Advisory Committee for Student Health, Princeton University
- 1996-present Member, American Clinical and Climatological Association
- 2007 Inductee, Nebraska High School Sports Hall of Fame
Lincoln, Nebraska
- 2008 Inductee, Old Blue Rugby Football Hall of Fame
New York, New York

E. Visiting Professorships and Invited Medical Grand Rounds

- October 6-7, 1993 Visiting Professor, Yale University School of Medicine
Pulmonary Division
- October 14, 1993 Visiting Professor, University of Pittsburgh
- March 14-15, 1994 Bailey K. Ashford Lecturer
University of Puerto Rico
San Juan, PR
- May 11-13, 1994 Visiting Professor, Duke University Medical Center
Department of Medicine
Durham, NC
- October 4, 1994 9th Annual Robert F. Johnston, M.D. Memorial Lecture
Hahnemann University
Philadelphia, PA
- October 5-6, 1994 Visiting Professor, Department of Medicine
Hahnemann University
Philadelphia, PA
- March 13-14, 1995 Visiting Professor,
Northwestern University Pulmonary Division
- November 29-30, 1995 Visiting Professor
University of Alabama at Birmingham
Birmingham, Alabama
- June 4, 1996 Bellevue Hospital, New York, NY
Department of Medicine, Medical Grand Rounds
- January 8, 1997 Visiting Professor
University of Kentucky, Dept. of Internal Medicine,
Division of Pulmonary and Critical Care Medicine
- March 3-7, 1997 Visiting Professor, University of Hawaii, Honolulu, Hawaii.
- September 5, 1997 Pennsylvania Thoracic Society; Pittsburgh. “Non-tuberculous
Mycobacterial Lung Disease: Diagnosis and Treatment”.
- September 12, 1997 Infectious Disease Society of America; San Francisco, CA.
“Drug-resistant Tuberculosis”.

- November 17, 1997 Australian Public Health Association; Sydney, Australia. Keynote Address: “Drug-resistant TB and DOT”.
- November 24, 1997 University of Utah, Salt Lake City, Utah, Medical Grand Rounds: “TB at the End of the 20th Century”.
- December 19, 1997 Southwestern School of Medicine; Dallas, Texas. Pulmonary Grand Grounds; “NTMsl Lung Disease”.
- January 14, 1998 University of Miami School of Medicine; Miami, Florida. Medical Grand Rounds: “Drug-resistant Tuberculosis”.
- February 19, 1998 Grand Rounds/Visiting Professor. Department of Medicine. Division of Pulmonary and Critical Care Medicine. Louisiana State University School of Medicine. New Orleans, Louisiana
- February 27, 1998 New Mexico Thoracic Society, Taos, New Mexico. “NTMsl Lung Disease in HIV-negative Persons.
- March 25, 1998 Washington, D.C. Infectious Disease Society; Washington, D.C. “Multidrug-resistant TB “
- August 3-4, 1998 Philippine College of Chest Physicians; Manila. “Recent Advances in TB Management: A Prescription for Noncompliance”.
- November 23, 1998 Japanese Anti-Tuberculosis Association Symposium, Bangkok, Thailand. “Multidrug-resistant TB”.
- February 5-6, 1999 Infectious Disease Society of Canada; Key West, Florida. “Mycobacteria Other than Tuberculosis”. “Drug-resistant TB”.
- February 24, 1999 Stanford Infectious Disease Course; Snowmass, CO. “Tuberculosis in Persons with AIDS”. “Preventive Therapy: Who Needs it?”
- March 15-18, 1999 University of Tartu, Symposium on TB; Tartu, Estonia. “Medical Management of MDR-TB”. “Surgical Management of MDR-TB”.
- March 28, 1999 Yale University Orthopedics Conference; Bermuda. “TB of the Bones”.
- May 27-29, 1999 UNESCO Conference on TB; Teheran, Iran. “Modern TB Chemotherapy: Short Course, Intermittent DOT”. “Management of MDR-TB”.

- June 3-5, 1999 Asian-Pacific Congress on Diseases of the Chest; Hong Kong, PRC. "MDR-TB". Plenary Lecture: "TB in the 21st Century".
- June 25-26, 1999 University of Monterrey TB Course; Monterrey, Mexico. "Medical-Surgical Management of MDR-TB".
- July 12-14, 1999 Argentina Thoracic Society, Buenos Aires, Argentina. "MDR-TB". "Non-tuberculous Mycobacterial Lung Disease".
- July 16-17, 1999 Thoracic Institute, Santiago, Chile. "Medical-Surgical Management of MDR-TB".
- August 31, 1999 Karolinska Institute; Stockholm, Sweden. "Clinical Management of MDR-TB".
- September 3, 1999 Scandinavian-Baltic Program on TB; Tallinn, Estonia. "Medical-Surgical Management of MDR-TB".
- October 31, 1999 American College of Chest Physicians; Chicago, Illinois. Louis Mark Memorial Lecture and Medal: "TB at the End of the 20th Century".
- November 3, 1999 American College of Chest Physicians; Chicago, Illinois. "Mycobacteria Other Than Tuberculous Lung Disease".
- November 5, 1999 University of Oregon Health Sciences Center; Portland, Oregon. "NTM Lung Disease".
- November 10, 1999 Connecticut Thoracic Society; Hartford, Connecticut. "NTMsl Lung Disease".
- November 21-24, 1999 Southern African Infectious Disease Society; Sun City, South Africa. Plenary Lecture: "MDR-TB and HIV-Infection".
- February 24, 2000 The North American Region of the IUATLD; Vancouver, British Columbia. The Pittsfield Lecture: "TB Elimination: A Quixotic Dream?"
- March 2-3, 2000 The Soros Open Society Institute Program on TB; Moscow, Russia. "Modern Short-course Therapy of TB". "Medical-Surgical Management of MDR-TB".
- March 27-28, 2000 Ukrainian TB Association Symposium; Kiev, Ukraine. "Medical-Surgical Management of MDR-TB".

- March 29, 2000 Russian Academy of Tuberculosis; Moscow, Russia. “Controlling the Emerging MDR-TB Epidemic”.
- March 31, 2000 Khazakhstan TB Association, Astana, Khazakhstan. “The Medical-Surgical Management of MDR-TB”.
- April 19, 2000 Japanese Anti-Tuberculosis Association Annual Meeting; Osaka, Japan. Plenary Lecture: “The Medical-Surgical Management of MDR-TB”.
- April 20, 2000 Osaka University School of Medicine; Osaka, Japan. “Preventing Nosocomial Transmission of MDR-TB”.
- May 6, 2000 American Thoracic Society Annual Meeting; Toronto, Canada. Post-Graduate Course on TB: “Treatment of Drug Susceptible and MDR-TB”.
- June 21, 2000 American Society of Microbiology; New York, New York. “TB Past, Present, and Future. Keynote Address: “National Jewish Hospital, A Century of TB Care”.
- July 17, 2000 Australian Infectious Disease Society; Palm Cove, Australia. “Management of MDR-TB”.
- October 3, 2000 University of Michigan Internal Medicine Review Course; An Arbor, Michigan. “Treatment and Prevention of TB”. “Pulmonary Disease Due to NTMs”.
- November 1, 2000 Jackson Memorial Hospital, Miami, Florida. Medical Grand Rounds: “TB and HIV”.
- November 10, 2000 Mayo Clinic Infectious Disease Course; Sedona, Arizona. “Guidelines for the Prevention of TB”. “Pulmonary NTM Disease”.
- December 19, 2000 North Shore Hospital; Huntington, Long Island. Grand Rounds. “TB in the Era of AIDS”.
- January 10, 2001 Queens Medical Center; Jamaica, New York. Medical Grand Rounds: “NTM Lung Disease in Normal Hosts”.
- January 11, 2001 Nassau County Medical Center; Hempstead, New York. “MDR-TB”.

- January 17, 2001 Stanford University Medical Center, Palo Alto, California. Pulmonary Research Conference: "NTMsl Lung Disease in Women: Why Me?"
- January 20-21, 2001 Washington State Thoracic Society; Leavenworth, Washington. "Treatment of Latent TB Infection". "MOTT Lung Disease".
- January 26, 2001 World Health Organization Regional Tuberculosis Meeting; Lima Peru. "Medical-Surgical Management of MDR-TB".
- March 9, 2001 Philippine College of Chest Physicians; Manila, Philippines. Plenary Lecture: "MDR-TB, The State of the Art".
- March 26, 2001 The Americas College of Physicians Annual Meeting; Atlanta, Georgia. The James D. Bruce Memorial Lecture: "MDR-Tuberculosis".
- April 2, 2001 Good Samaritan Hospital; Phoenix, Arizona. Medical Grand Rounds: "NTM Lung Disease".
- April 11, 2001 Henry Ford Hospital; Detroit, Michigan. Medical Grand Rounds: "Medical-Surgical Management of NTM Lung Disease".
- April 19, 2001 Beth Israel Hospital; Boston, Massachusetts. Medical Grand Rounds: "TB in the 21st Century: The Role of Preventive Therapy".
- April 28, 2001 Infectious Disease Association of California Annual Meeting; Santa Barbara, California. "NTMsl Lung Disease".
- May 8, 2001 Dupont Hospital Infectious Disease Review Course; Wilmington, Delaware. "The New Guidelines for the Treatment of Latent TB Infection".
- May 18, 2001 American Thoracic Society Annual Meeting; San Francisco, California. Post-Graduate Course on Tuberculosis: "Medical-Surgical Management of MDR-TB".
- May 29, 2001 American College Health Association Annual Meeting; Las Vegas, Nevada. "TB in Student Health Programs".
- June 12, 2001 Chicago Thoracic Society; Chicago, Illinois. "Pulmonary MOTT Disease".

- June 21, 2001 Pennsylvania Thoracic Society Annual Meeting; Pittsburgh, Pennsylvania. "Nontuberculous Lung Disease in Women: Why Me?"
- July 17-18, 2001 TB Research Institute of the Urals; Yekaterinberg, Russia. "Medical-Surgical Management of MDR-TB".
- October 30, 2001 Medical Grand Rounds: "Pulmonary TB 2001: An Update on Diagnosis and Therapy". Pulmonary and Critical Care Medicine, Medical University of South Carolina. Charleston, South Carolina
- November 6-7, 2001 American College of Chest Physicians, Annual Meeting, Philadelphia. "Epidemiology and Risk Factors for NTM Lung Disease". "Serious Pulmonary Infections: TB". "Global Perspective on TB".
- November 20, 2001 University of Virginia, Visiting Professor in Infectious Diseases. "NTMsl Lung Diseases".
- December 14, 2001 Wilford Hall Air Force Medical Center. "NTMsl Lung Diseases".
- January 16, 2002 University of Pennsylvania, Infectious Diseases Grand Rounds: "Treatment of Latent Tuberculosis Infection".
- January 25, 2002 Barcelona, Spain. The European Institute of Health Care. "Current and Future Therapy of TB".
- February 8, 2002 Sacramento, CA. University of California (Davis) Infectious Diseases Course. "TB Control and Treatment of Latent TB Infections".
- February 14, 2002 Salt Lake City, UT. University of Utah Medicine Grand Rounds. "Research on TB Therapy in the 3rd World: Good Science is Good Science"
- June 23-July 5, 2002 Moscow, Russia. World Health Organization . Invited Lecture "MDR-TB"
- September 4, 2002 Mineola, NY. Winthrop Hospital Medicine Grand Rounds. NTMs

- September 26, 2002 Manila, Philippines. Thoracic Society Lectures
“TB Antiquity to the 21st Century”
“Transmission and Infection Control”
“TST and TLTI”
- October 8, 2002 Montreal, Canada. International Union Against Tuberculosis and Lung Disease. Jindani Lecture.
“MDR-TB”
- October 11, 2002 Baltimore, MD. Johns Hopkins Medical Center
Festschrift. Comstock’s Impact on TB Control in the US
- November 5, 2002 San Diego, CA. American College of Chest Physicians.
“Medical and Surgical Management of NTMs”
- March 20, 2003 St. Louis, MO. Washington University/Barnes Jewish Hospital
Visiting Lectureship
“NTMs”
- April 11, 2003 New York, NY Bellevue Chest Services Division
“MDR-TB”
- April 30, 2003 New Orleans, LA. Tulane University Infectious Diseases Grand Rounds
“MDR-TB”
- May 1, 2003 New Orleans, LA. New Orleans Citywide TB Conference
“New Aspects of TLTI”
- May 2, 2003 New Orleans, LA. New Orleans Citywide TB Conference
“Global Issues on TB”
- May 16, 2003 Davis, CA. University of California, Davis. Invited Lectures:
“Tuberculosis” and “NTMs and Bronchiectasis”
- May 20, 2003 American Thoracic Society Invited Lectures
“RGMs and AAT”
- May 21, 2003 American Thoracic Society Invited Lectures
“Bronchiectasis and NTM”
- July 17, 2003 Anchorage, AK. State TB Controllers Meeting:
“Tuberculosis” and “NTMs”

- September 16, 2003 Ann Arbor, MI. University of Michigan Pulmonary Course
“TLTI” and “NTMs”
- September 21, 2003 Philadelphia, PA. Pennsylvania Thoracic Society
“Nontuberculous Mycobacteria”
- October 27, 2003 Orlando, FL. American College of Chest Physicians.
“Diagnosis of NTMs”
- October 28, 2003 Orlando, FL. American College of Chest Physicians.
“Bronchiectasis”
- October 29, 2003 Orlando, FL. American College of Chest Physicians.
“New Approaches to TB Treatment”
- November 3, 2003 Newark, NJ. Public Health Research Institute
College of Medicine and Dentistry of New Jersey
“Drug Resistant TB”
- November 11, 2003 Newark, NJ. Medical Grand Rounds
College of Medicine and Dentistry of New Jersey
“Global TB Control”
- November 13-14, 2003 Tomsk, Siberia. Partners in Health:
“Drug Resistant TB Treatment”
- January 30, 2004 West Point, NY New York State Thoracic Society Trudeau
Lecture
“MDR-TB”
- March 7, 2004 Arlington, VA. American Thoracic Society State of the Art
Course
“TB” and “NTMs”
- March 25, 2004 St. Louis, MO. Washington University Pulmonary Grand
Rounds
“NTMs”
- May 13, 2004 New York, NY. Columbia College of Physicians and Surgeons
Medical Grand Rounds
“NTMs”
- May 25, 2004 American Thoracic Society Annual Meeting Invited Lecture
“Role of Surgery in NTM”

June 22, 2004	Tomsk, Siberia. Partners in Health. “MDR”
September 21, 2004	Montclair, NJ State Infectious Diseases Society. “NTMs”
October 6, 2004	Baltimore, MD. Dannenberg Symposium: Johns Hopkins “Vaccination for TB”
October 27, 2004	American College of Chest Physicians Invited Lecture “Management of TB”
October 30, 2004	Paris, France. International Union Against Tubercle and Lung Disease Invited Lecture “MDR-TB”
November 11, 2004	Washington, DC. Georgetown Medical Grand Rounds “Update on NTM”
January 11, 2005	Oneonta, NY. Hartwich College. “TB and HIV in the Modern World”
January 12, 2005	Oneonta, NY. Bassett Hospital Grand Rounds “NTM”
January 21, 2005	Los Angeles, CA. UCLA Pulmonary Review Course Invited Lecture “TB Treatment and Prevention” “NTM Lung Disease”
February 17, 2005	Stanford, CA. Stanford Infectious Disease Course “MDR-TB” “TLTI”
April 4, 2005	Glen Cove, NY. North Shore Hospital Medical Grand Rounds “NTMs”
April 17, 2005	Toronto, Canada. Canadian Infectious Diseases Society Plenary Lecture “Update on TB”
April 27, 2005	Antalya, Turkey. Turkey Thoracic Society “MDR-TB”

May 6, 2005	Philadelphia, PA. Pennsylvania Thoracic Society Figueroa Lecture “MAC”
September 16, 2005	Ponta Vedra, FL. Tri-State TB Conference “Surgery in MDR-TB”
October 20, 2005	Gainesville, FL. University of Florida Pulmonary Grand Rounds “Update on TB”
October 31, 2005	Montreal, Canada. American College of Chest Physicians “Diagnosis and Treatment of MDR”
November 2, 2005	Montreal, Canada. American College of Chest Physicians “Diagnosis and Treatment of Bronchiectasis”
May 4, 2006	Little Rock, AR. Joseph Bates Lecture “TB in the 21 st Century”
May 11, 2006	New York, NY. Memorial Sloan Kettering Medical Grand Rounds “NTM”
May 19, 2006	San Diego, CA. American Thoracic Society Preconference Course “MDR-TB”
May 23, 2006	San Diego, CA. American Thoracic Society Preconference Course “Management of RGMs”
May 24, 2006	San Diego, CA. American Thoracic Society Preconference Course “TB Year in Review”
June 3, 2006	Princeton, NJ. Princeton University Alumni Faculty Forum “TB and HIV in the World”
June 23, 2006	Dublin, Ireland. College of Medicine “Update on TB” “NTMs”
July 6-7, 2006	Cancun, Mex. Mexico Thoracic Society “MDR-TB”, “DOT” and “NTM”

- September 14-15, 2006 San Antonio, TX. Wilford Hall Air Force Base/Brooke Army Medical Center Visiting Professor:
“MDR-TB”, “TLTI” and “NTM”
- October 18, 2006 Nashville, TN. Southeast National TB Controllers’ Meeting
Keynote Address
“TB in the 21st Century”
- October 22, 2006 Salt Lake City, UT. American College of Chest Physicians
Murray Kornfeld Honorary Lecture
“TB and HIV in the 21st Century”
- November 2, 2006 Denver, CO. Cystic Fibrosis Meeting
“*M. abscessus* in Cystic Fibrosis”
- February 9, 2007 Miami, FL. Alpha Anti-trypsin Foundation
“NTMs and AAT”
- February 22, 2007 Vancouver, BC. North American Region of IUATLD
“New Diagnostic Tools in TB”
- February 24, 2007 Vancouver, BC. North American Region of IUATLD; Plenary
Lecture
“Progress in TB”
- March 17, 2007 Denver, CO. Schrier Award
- July 11, 2007 Washington, DC. National Press Club/NFID
“New Treatment in MDR-TB”
- August 6, 2007 Longmont, CO. “Colorado Responds to MDR-TB”. Keynote
Speaker
“The Future of Drug Resistant TB and AIDS”
- September 21, 2007 Denver, CO. APIC:
“Protecting Health Care Workers Against MDR-TB”
- October 12, 2007 Boise, ID. John Butler Conference. Leonard Hudson Achievement
Award
“The Future of Drug-Resistant TB and AIDS”
- October 29, 2007 Durango, CO. Four Corners TB Conference Keynote Address
“MDR-TB, A Global Challenge, A Local Issue”

November 7-8, 2007	New Haven, CT. Visiting Professor “MDR-TB” “NTM”
November 28, 2007	Louisville, KY. Southeast TB Controllers’ Meeting Keynote Speaker “MDR-TB”
December 2, 2007	Denver, CO. St. Joseph Hospital Medical Grand Rounds “Update on TB”
February 18-20, 2008	Maui, HI. Hawaii Thoracic Society “MDR-TB” “NTM”
March 25, 2008	Newark, NJ. Reynard McDonald Lecture “XDR-TB”
April 3, 2008	Orlando, FL. American Society for Clinical Pharmacology “Drug Resistant TB”
April 30-May 2, 2008	Omaha, NE. Irving Kass Visiting Professor “Drug Resistant TB and AIDS” “NTMs”
May 8-10, 2008	Louisville, KY. University of Kentucky Pulmonary Update “Drug Resistant TB and AIDS” “NTM”
May 20, 2008	Toronto, Canada. American Thoracic Society Clinical Expert: TB and NTMs

VII. Patents: None

VIII. Review and Referee Activities:

1984-1989	Associate Editor, <i>American Review of Respiratory Disease</i>
1976-present	Reviewer, <i>American Review of Respiratory Disease</i>
1976-present	Reviewer, <i>Chest</i>
1982-present	Reviewer, <i>Annals of Internal Medicine</i>
1990-present	Reviewer, <i>The New England Journal of Medicine</i> ,
1993-present	Reviewer, <i>Clinical Infectious Diseases</i>
1994-present	Reviewer, <i>Antimicrobial Agents & Chemotherapy</i>
1995-present	Reviewer, <i>Journal of the American Medical Association</i>
1995-1996	Editor-in-Chief, <i>Tubercle and Lung Disease</i>

1997-2002 Editor-in-Chief, *The International Journal of Tuberculosis and Lung Disease*

IX. Teaching Activities:

1983-present Course Director, Clinical Management and Control of Tuberculosis. National Jewish Medical and Research Center, 3 times yearly (average annual attendance, 225).

1982-1996 Attending Physician, NJC inpatient service (2-4 mos/year); teaching pulmonary and infectious disease fellows.

1989-present Attending Physician, NJC outpatient clinic (1/2 day/week); teaching infectious disease fellows.

1996-present Attending physician, 3 to 5 months per year, Adult Day Unit, National Jewish Medical and Research Center, teaching infectious disease Fellows.

1996-1998 Attending physician, one month per year, University Hospital General Medicine or 6E National Jewish Service, Teaching Medical Residents.

X. Research Grants, Contracts, and Special Grants

A. Current Research Grant Support: None

B. Previous Grant Support: (Principal Investigator)

NIH Contract No. 1-AI-42544, Development and Evaluation of Drugs for Treatment of M. avium-intracellulare Infection in AIDS and Other Patients, 1984-1987 (\$720,573).

NIH Contract No. 1-AI-72636, Development and Evaluation of Drugs for Treatment of *M. avium-intracellulare* infections, 1987-1992 (\$1,780,011).

NIH Contract No. 1-AI-52574, Classification of Clinically Important NTMs Isolated from AIDS and other Immunocompromised Patients, 1985-1990 (\$664,774).

XI. Bibliography

A. Original Articles in Refereed Journals

1. Hobby GL, Holman AP, Iseman MD, et al: Enumeration of tubercle bacilli in sputum of patients with pulmonary tuberculosis. *Antimicrobial Agents and Chemotherapy* 4:94, 1973.

2. Matthay RA, Neff TA, Iseman MD: Tuberculosis pleural effusions developing during chemotherapy for pulmonary tuberculosis. *American Review of Respiratory Disease* 109:469, 1974.
3. Pierson DJ, Iseman MD, Sutton FD, et al: Arterial blood gas changes in fiberoptic bronchoscopy during mechanical ventilation. *Chest* 66:495, 1974.
4. Potts D, Mass MF, Iseman MD: The syndrome of pancreatic disease, subcutaneous fat necrosis and polyserositis. *American Journal of Medicine* 58:417, 1975.
5. Albert RK, Sbarbaro JA, Hudson LH, Iseman MD: High dose ethambutol: its role in intermittent chemotherapy, a six-year study. *American Review of Respiratory Disease* 114:699, 1974.
6. Albert RK, Iseman MD, Sbarbaro JA, et al: Monitoring tuberculosis patients for failure during and after treatment. *American Review of Respiratory Disease* 114:1051, 1976.
7. Iseman MD, Schwarz MI, Stanford RE: Interstitial pneumonia in angioimmunoblastic lymphadenopathy with dysproteinemia--a case report with special histopathologic studies. *Annals of Internal Medicine* 85:752, 1976.
8. Haynes BJ and Iseman MD: Massive pulmonary embolism presenting with hypercapnia and minimal intrapulmonary shunting. *The Rocky Mountain Medical Journal*, pp. 135-137, 1979.
9. Good JT, Iseman MD, Davidson PT, Lakshminarayan S, and Sahn SA: Tuberculosis in association with pregnancy. *American Journal of Obstetrics and Gynecology* 140(5):492-498, 1981.
10. Heifets LB, Iseman MD: Radiometric method for testing susceptibility of mycobacteria to pyrazinamide in 7H12 broth. *Journal of Clinical Microbiology* 21(2):200-204, 1985.
11. Horsburgh, Jr. CR, Mason UG, Farhi DC, and Iseman MD: Disseminated infection with *Mycobacterium avium intracellulare*: a report of 13 cases and a review of the literature. *Medicine* 64(1):36-48, 1985.
12. Heifets LB, Iseman MD, Cook JL, Lindholm-Levy PJ, and Drupa I: Determination of *in vitro* susceptibility of *Mycobacterium tuberculosis* to cephalosporins by radiometric and conventional methods. *Antimicrobial Agents and Chemotherapy* 27(1):11-15, 1985.

13. Heifets LB and Iseman MD: Determination of *in vitro* susceptibility of mycobacteria to ansamycin. *American Review of Respiratory Disease* 132:710-711, 1985.
14. Heifets LB, Iseman MD, Lindholm-Levy PJ, and Kanen W: Determination of ansamycin MICs for *Mycobacterium avium* complex in liquid medium by radiometric and conventional methods. *Antimicrobial Agents and Chemotherapy* 28(4):570-575, 1985.
15. Perumal VK, Gangadharam PRJ, Heifets LB, and Iseman MD: Dynamic aspects of the *in vitro* chemotherapeutic activity of ansamycin on *M. intracellulare*. *American Review of Respiratory Disease* 132:1278-1280, 1985.
16. Krause PJ, Hight DW, Schwartz AW, Mueller RE, Kleinman L, Leopold H, and Iseman MD: Successful management of *M. intracellulare* pneumonia in a child. *Pediatric Infectious Disease* 5(2):269-271, 1986.
17. Dunn TL, Gerber MJ, Shen AS, Fernandez E, Iseman MD, and Cherniack RM: The effect of topical ophthalmic instillation of timolol and betaxolol on lung function in asthmatic subjects. *American Review of Respiratory Disease* 133:264-268, 1986.
18. Heifets LB, Iseman MD, Crowle AJ, and Lindholm-Levy PJ: Pyrazinamide is not active *in vitro* against *Mycobacterium avium* complex. *American Review of Respiratory Disease* 134:1287-1288, 1986.
19. Heifets LB, Iseman MD, and Lindholm-Levy PJ: Ethambutol MICs and MBCs for *Mycobacterium avium* complex and *M. tuberculosis*. *Antimicrobial Agents and Chemotherapy* 30:927-932, 1986.
20. Horsburgh CR, Cohn DL, Roberts RB, Masur H, Miller RA, Tsang AY, and Iseman MD: *Mycobacterium avium*-*M. intracellulare* isolates from patients with or without acquired immunodeficiency syndrome. *Antimicrobial Agents and Chemotherapy* 30:955-957, 1986.
21. Horsburgh CR, Mason UG, Heifets LB, Southwick K, LaBrecque J, Iseman MD: Response to therapy of pulmonary *Mycobacterium avium*-*intracellulare* infection correlates with results of *in vitro* susceptibility testing. *American Review of Respiratory Disease* 135:418-421, 1987.
22. Shen A, Iseman MD, Waldron JA, and King TE: Exacerbation of pulmonary lymphangioleiomyomatosis by exogenous estrogens. *Chest* 91:782-785, 1987.

23. Heifets LB, Iseman MD, and Lindholm-Levy PJ: Determination of MICs of conventional and experimental drugs in liquid medium by the radiometric method against *Mycobacterium avium* complex. *Drugs in Experimental and Clinical Research* 13(9):529-538, 1987.
24. Perumal VK, Gangadharam PRJ, and Iseman MD: Effect of rifabutin on the phagocytosis and intracellular growth of *Mycobacterium intracellulare* in mouse resident and activated peritoneal and alveolar macrophages. *American Review of Respiratory Disease* 136:334-337, 1987.
25. Heifets LB, Iseman MD, and Lindholm-Levy P: Combinations of rifampin or rifabutin plus ethambutol against *Mycobacterium avium* complex: bactericidal synergistic, and bacteriostatic additive or synergistic effects. *American Review of Respiratory Disease* 137:711-715, 1988.
26. Heifets LB, Iseman MD, and Lindholm-Levy P: Rifabutin: minimal inhibitory and bactericidal concentrations for *M. tuberculosis*. *American Review of Respiratory Disease* 137:719-721, 1988.
27. Gangadharam PRJ, Perumal VK, Podapati NR, Kesavalu L, and Iseman MD: *In vivo* chemotherapeutic activity of amikacin alone or in combination with clofazimine or rifabutin or both against acute experimental *Mycobacterium avium* complex (MAC) infections in beige mice. *Antimicrobial Agents and Chemotherapy* 32:1404-1411, 1988.
28. Gangadharam PRJ, Kesavalu L, Podapati NRR, Perumal VK, and Iseman MD: Activity of amikacin against *Mycobacterium avium* complex under simulated *in vivo* conditions. *Antimicrobial Agents and Chemotherapy* 32:886-889, 1988.
29. Iseman MD, Madsen L, Goble M, and Pomerantz M: Surgical intervention in the treatment of pulmonary disease caused by drug-resistant *Mycobacterium tuberculosis*. *American Review of Respiratory Disease* 141:623-625, 1990.
30. Gangadharam PRJ, Pratt PF, Perumal VK, and Iseman MD: The effects of exposure time, drug concentration, and temperature on the activity of ethambutol versus *Mycobacterium tuberculosis*. *American Review of Respiratory Disease*. 141:1478-1482, 1990.
31. Manalo F, Tan F, Sbarbaro JA, and Iseman MD: Community based short-course treatment of pulmonary tuberculosis in a developing nation. Initial report of an eight-month, largely intermittent regimen in a population with high prevalence of drug resistance. *American Review of Respiratory Disease* 142:1301-1305. 1990.
32. Iseman, MD and Madsen LA: Chronic tuberculous empyema with bronchopleural fistula resulting in treatment failure and progressive drug resistance. *Chest* 100:124-127, 1991.

33. Iseman MD, Buschman DL, and Ackerson LM: Pectus excavatum and scoliosis: thoracic anomalies associated with pulmonary disease due to *M. avium* complex. *American Review of Respiratory Disease* 144:914-916, 1991.
34. Pomerantz M, Madsen L, Goble M, and Iseman M. Surgical management of resistant mycobacterial tuberculosis and other mycobacterial pulmonary infections. *Ann Thorac Surg* 52:1108-12, 1991.
35. Sbarbaro JA, Iseman MD, and Crowle AJ. The combined effect of rifampin and pyrazinamide within the human macrophage. *American Review of Respiratory Disease* 146:1448-1451, 1992.
36. Nitta AT, Iseman MD, Newell JD, Madsen LA, Goble M. Ten-year experience with artificial pneumoperitoneum for end-stage, drug-resistant pulmonary tuberculosis. *Clin Infec Dis* 16:219-222, 1993.
37. Goble M, Iseman MD, Madsen LA, Waite D, Ackerson L, Horsburgh CR. Treatment of 171 patients with pulmonary tuberculosis resistant to isoniazid and rifampin. *N Engl J Med* 328(8):527-532, 1993.
38. Iseman MD. Treatment of multidrug-resistant tuberculosis. *New England Journal of Medicine* 329:784-791, 1993.
39. Mahmoudi A and Iseman MD. Pitfalls in the care of patients with tuberculosis. Common errors and their association with the acquisition of drug resistance. *JAMA* 270:65-68, 1993.
40. Ellner JJ, Hinman AR, Dooley SW, Fischl MA, Sepkowitz KA, Goldberger MJ, Shinnick TM, Iseman MD, Jacobs WR. Tuberculosis Symposium: Emerging problems and promise. *J Infec Dis* 168:537-51, 1993.
41. Cohn DL, Iseman MD. Treatment and prevention of multidrug-resistant tuberculosis. *Review of Microbiology* 144:150-153, 1993.
42. Peloquin CA, James GT, Craig LD, Kim M, McCarthy EA, Ikle D, Iseman MD. Pharmacokinetic evaluation of aconiazide, a potentially less toxic isoniazid prodrug. *Pharmacotherapy* 14(4):415-423, 1994.
43. Berning SE, Madsen L, Iseman MD, Peloquin CA. Long-term safety of ofloxacin and ciprofloxacin in the treatment of mycobacterial infections. *Am J Respir Crit Care Med* 151:2006-2009, 1995.
44. Elliott AM, Berning SE, Iseman MD, Peloquin CA. Failure of drug penetration and acquisition of drug resistance in chronic tuberculous empyema. *Tuberc Lung Dis* 76:463-467, 1995.

45. Peloquin CA, Berning SE, Madsen L, Iseman MD. Ofloxacin and ciprofloxacin in the treatment of mycobacterial infections: development of resistance and drug interactions. *J Infect Dis Pharmacother* 1:45-65, 1995.
46. Morgan MB, Iseman MD. *Mycobacterium bovis* vertebral osteomyelitis as a complication of intravesical administration of Bacille Calmette-Guérin. *Amer J Med* 100:372-373., 1996.
47. Pomerantz M, Denton JR, Huitt GA, Brown JM, Powell LA, Iseman MD. Resection of the right middle lobe and lingula for mycobacterial infection. *Ann Thorac Surg* 62:990-993, 1996.
48. Berning SE, Iseman MD. Rifamycin-induced lupus syndrome. *The Lancet* 349:1521-1522, 1997.
49. Iseman MD. Tuberculosis of the Pleural Space. *Seminars in Respiratory Infections*, 13(4), 1998.
50. Chan ED, Iseman MD. Potential association between calcified thoracic lymphadenopathy due to previous *Histoplasma capsulatum* infection and pulmonary *Mycobacterium avium* complex disease. *Southern Medical Journal*, 92(6):572-576, 1999.
51. Iseman, MD. Vulnerability to tuberculosis and William Stead, a tireless scholar. *Int J Tuberc Lung Dis*, 5:983, 2001.
52. Iseman, MD. Some healthy skepticism about inhaled therapy for tuberculosis. *Clin Infect Dis* 33:266-267, 2001.
53. Berning SE, Cherry TA, and Iseman MD. Novel treatment of meningitis caused by multidrug-resistant *Mycobacterium tuberculosis* with intrathecal Levofloxacin and Amikacin: Case report. *Clin Infect Dis* 32:643-6, 2001.
54. Iseman MD. A 52-year-old man with a positive PPD. *JAMA*, October 23/31, 286(16):2015-22, 2001.
55. Chan ED, Kong P-M, Fennelly K, Dwyer AP, Iseman MD. Vertebral osteomyelitis due to infection with non-tuberculous *Mycobacterium* species after blunt trauma to the back: 3 examples of the principle of locus minoris resistentiae. *Clin Infect Dis* 32:1506-1510, 2001.
56. Iseman MD. A new approach to treating patients with MDR-TB? *Int J Tuberc Lung Dis* 6:1037, 2002.

57. Heifets L, Iseman MD. Leo Tolstoy, TB in Russia, and American perceptions. *Int J Tuberc Lung Dis* 6:939-941, 2002.
58. Chan ED, Iseman MD. Current medical treatment for tuberculosis. *BMJ* 325:1282-1286, 2002.
59. Iseman MD. Medical management of pulmonary disease caused by Mycobacterium avium complex. *Clin Chest Med* 23:633-641, vii, 2002.
60. Iseman MD. Tuberculosis therapy: past, present and future. *Eur Respir J Suppl* 36:87s-94s, 2002.
61. Iseman MD, Petty TL. Not just another researcher. *Nat Med* 8:426, 2002.
62. Fennelly K, Iseman MD. Etanercept or mycobacterium lung injury? *Chest* 124:1174; author reply 1174-1175, 2003.
63. Blumberg HM, Burman WJ, Chaisson RE, Daley CL, Etkind SC, Friedman LN, Fujiwara P, Grzemska M, Hopewell PC, Iseman MD, Jasmer RM, Koppaka V, Menzies RI, O'Brien RJ, Reves RR, Reichman LB, Simone PM, Starke JR, Vernon AA. American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America: treatment of tuberculosis. *Am J Respir Crit Care Med* 167:603-662, 2003.
64. Chan ED, Laurel V, Strand MJ, Chan JF, Huynh ML, Goble M, Iseman MD. Treatment and outcome analysis of 205 patients with multidrug-resistant tuberculosis. *Am J Respir Crit Care Med*. 2004 May 15;169(10):1103-9.
65. Peloquin CA, Berning SE, Nitta AT, Simone PM, Goble M, Huitt GA, Iseman MD, Cook JL, Curran-Everett D. Aminoglycoside toxicity: daily versus thrice-weekly dosing for treatment of mycobacterial diseases. *Clin Infect Dis*. 2004 Jun 1;38(11):1538-44.
66. Rodman DM, Polis JM, Heltshe SL, Sontag MK, Chacon C, Rodman RV, Brayshaw SJ, Huitt GA, Iseman MD, Saavedra MT, Taussig LM, Wagener JS, Accurso FJ, Nick JA. Late diagnosis defines a unique population of long-term survivors of cystic fibrosis. *Am J Respir Crit Care Med*. 2005 Mar 15;171(6):621-6.
67. Chmura K, Chan ED, Noone PG, Zariwala M, Winn RA, Knowles MR, Iseman MD, Gardner EM. A middle-aged woman with recurrent respiratory infections. *Respiration*. 2005 Jul-Aug;72(4):427-30.
68. Gelperina S, Kisich K, Iseman MD, Heifets L. The potential advantages of nanoparticle drug delivery systems in chemotherapy of tuberculosis. *Am J Respir Crit Care Med*. 2005 Dec 15;172(12):1487-90.

69. Iseman MD, Heifets LB. Rapid detection of tuberculosis and drug-resistant tuberculosis. *N Engl J Med*. 2006 Oct 12;355(15):1606-8.
70. Chan ED, Kaminska AM, Gill W, Chmura K, Feldman NE, Bai X, Floyd CM, Fulton KE, Huitt GA, Strand MJ, Iseman MD, Shapiro L. Alpha-1-antitrypsin (AAT) anomalies are associated with lung disease due to rapidly growing mycobacteria and AAT inhibits Mycobacterium abscessus infection of macrophages. *Scand J Infect Dis*. 2007;39(8):690-6.
71. Falkinham JO 3rd, Iseman MD, de Haas P, van Soolingen D. Mycobacterium avium in a shower linked to pulmonary disease. *J Water Health*. 2008 Jun;6(2):209-13.
72. Chan ED, Iseman MD. Significance of bronchiectasis in patients with alpha-1-antitrypsin deficiency. *Am J Respir Crit Care Med*. 2008 Jul 15;178(2):208; author reply 208-9.
73. Schwiesow JN, Iseman MD, Peloquin CA. Concomitant use of voriconazole and rifabutin in a patient with multiple infections. *Pharmacotherapy*. 2008 Aug;28(8):1076-80.

Books

Iseman MD. *A Clinician's Guide to Tuberculosis*. Philadelphia: Lippincott, Williams & Wilkins, 2000.

Book Chapters

1. Iseman MD: Flexible fiberoptic bronchoscopy. In: *Pulmonary Diagnostic Techniques* Ed. T. Petty. Philadelphia: Lea and Febiger. 133-155, 1975.
2. Iseman MD: Tuberculosis. In: *Current Pulmonology Vol. II*. Ed. D. Simmons. Boston: Houghton Mifflin, 1979.
3. Hanson FN and Iseman MD: Infectious pneumonias. In: *Synopsis of Clinical Pulmonary Disease, 3rd Edition*.. Ed. R. Mitchell and T. Petty. St. Louis: C. V. Mosby, 34-50, 1982.
4. Iseman MD: Extrapulmonary tuberculosis. In: *Synopsis of Clinical Pulmonary Disease, 3rd Edition*. Ed. R. Mitchell and T. Petty. St. Louis: C. V. Mosby, 151-158, 1982.

5. Iseman MD: Developmental anomalies of the lung and thorax. In: *Synopsis of Clinical Pulmonary Disease*. Ed. R. Mitchell and T. Petty. St. Louis: C. V. Mosby, 307-313-308, 1982.
6. Iseman MD: Pulmonary diseases of unknown etiology. In: *Synopsis of Respiratory Disease, 3rd Edition*. Ed. R. Mitchell and T. Petty. St. Louis: C. V. Mosby, 314-326, 1982.
7. Iseman MD: Tuberculosis section, "Medical Aspects of Homelessness." In: *The Homeless Mentally Ill* (A Task Force Report of the American Psychiatric Association). Ed. H. R. Lamb. Washington, DC: American Psychiatric Association, 253-258, 1984.
8. Iseman MD: Tuberculosis: an overview. In: *Health Care of Homeless People*. Ed. P. W. Brickner et al. New York: Springer Publishing Company, Inc., 151-154, 1985.
9. Gangadharam PRJ and Iseman MD: Antimycobacterial Drugs. In: *The Antimicrobial Agents Annual - 1*. Ed. P. K. Peterson and J. Verhoef. Amsterdam: El Sevier Science Publishers, 17-40, 1986.
10. Iseman MD: *Mycobacterium avium-intracellulare* Infection. In: *Current Therapy of Respiratory Disease - 2*. Ed. R. M. Cherniack. Toronto, Philadelphia: B. C. Decker, Inc, 91-94, 1986.
11. Heifets LB, Iseman MD, and Lindholm-Levy PJ: Bacteriostatic and Bactericidal Effects of Rifabutin (Ansamycin LM 427) on *Mycobacterium avium* Clinical Isolates. In: *Mycobacteria of Clinical Interest*. Ed. M. Casal. Amsterdam: El Sevier Science Publishers, 180-184, 1986.
12. Gangadharam PRJ and Iseman MD: Antimycobacterial Drugs. In: *The Antimicrobial Agents Annual - 2*. Ed. P. K. Peterson and J. Verhoef. Amsterdam: El Sevier Science Publishers, 14-35, 1987.
13. Iseman MD and Goble M: Treatment of Tuberculosis. In: *Advances in Internal Medicine - Volume 33*. Ed. G. Stollerman. Chicago: Year Book Medical Publishers, 253-265, 1988.
14. McClellan M and Iseman MD: Infectious Pneumonias in the Immunocompetent Host. In: *Synopsis of Clinical Pulmonary Disease., 4th Edition*. Ed. R. Mitchell, T. Petty, and M. Schwarz. St. Louis: C. V. Mosby, 60-70, 1989.
15. Iseman MD: Atypical Mycobacterial Diseases. In: *Synopsis of Clinical Pulmonary Disease, 4th Edition*. Ed. R. Mitchell, T. Petty, and M. Schwarz. St. Louis: C. V. Mosby, 85-91, 1989.

16. Iseman MD: Tuberculosis. In: *Synopsis of Clinical Pulmonary Disease, 4th Edition*. Ed. R. Mitchell, T. Petty, and M. Schwarz. Saint Louis: C. V. Mosby, 92-100, 1989.
17. Iseman MD and Madsen LA: Drug-Resistant Tuberculosis. *Clinics in Chest Medicine* 10:342-353, 1989.
18. Iseman MD: NTMsl infections. In: *Infectious Diseases*. Ed. SL Gorbach, JG Bartlett, and NR Blacklow. Philadelphia: W.B. Saunders Company, 1246-1256, 1992.
19. Iseman MD and Sbarbaro JA: The increasing prevalence of resistance to anti-tuberculosis chemotherapeutic agents: Implications for global tuberculosis control. *Current Clinical Topics in Infectious Diseases* 12:188-207, 1992.
20. Elliott AM, Iseman MD. The medical management of disease caused by drug-susceptible *Mycobacterium tuberculosis*. *Chest Surgery Clinics of N. America* 3(4):707-713, 1993.
21. Madsen LA, Iseman MD. Management of drug-resistant tuberculosis. *Chest Surgery Clinics of N. America* 3(4):715-721, 1993.
22. Mahmoudi A, Iseman MD. Medical management of mycobacteria other than tuberculosis. *Chest Surgery Clinics of N. America* 3(4):729-736, 1993.
23. Iseman MD. Evolution of drug-resistant tuberculosis: A tale of two species. In: National Academy of Sciences *Infectious Diseases in an Age of Change*. Ed. Bernard Roizman. Washington, DC: National Academy Press. 135-140, 1995.
24. Iseman MD. Pulmonary disease due to *Mycobacterium avium* complex. In: *Mycobacterium avium-Complex Infection. Progress in Research and Treatment*. Ed. JA Korvick and CA Benson. Lung Biology in Health and Disease, Vol. 87. Marcel Dekker, Inc.: New York, Basel, Hong Kong: 45-77, 1995.
25. Iseman MD. Tuberculosis. In: *Cecil Textbook of Medicine (20th Ed.)*. Ed. Bennett and Plum. Philadelphia: W.B. Saunders Company: 1683-1689, 1996.
26. Iseman MD. Guest Editors. Tuberculosis. *Clinics in Chest Medicine* Philadelphia: W.B. Saunders Company. 18(1):1-168, 1997.
27. Iseman MD and Huitt GA: NTMsl infections. In: *Infectious Diseases*. 2nd Edition. Ed. SL Gorbach, JG Bartlett, and NR Blacklow. Philadelphia: W.B. Saunders Company: 1513-1528, 1998.

28. Iseman, MD. Infections due to Non-tuberculous Mycobacteria. In: *Medical Management of Pulmonary Disease*. 2nd Edition. Eds. GS Davis, TW Marcy, EA Seward, BE Sobel. New York, Marcel Dekker, Inc., 1998.
29. Peloquin CA, Iseman MD. Antimycobacterial Agents. In Root RK, Ed. *Clinical Infectious Diseases: A practical approach* (Chapter) 1998.
30. Iseman MD. Group IV: Rapid-Growing Mycobacteria. In: *Antimicrobial Therapy and Vaccines*. Eds. VL Yu, TC Merigan, Jr., SL Barriere. Assoc. Eds. AM Sugar, D Raoult, C Peloquin, MD Iseman. Baltimore: Williams & Wilkins: 494-497, 1999.
31. Iseman MD. Infections due to NTMs. In: *Medical Management of Pulmonary Diseases*. Ed. GS Davis: 1999.
32. Iseman MD. Tuberculosis. In: *Cecil Textbook of Medicine (21st Ed.)*. Ed. L Goldman and JC Bennett. Philadelphia: W.B. Saunders Company: 1683-1689, 2000.
33. Iseman MD, Huitt GA. Treatment of Multidrug-resistant Tuberculosis. In: *Multidrug-Resistant Tuberculosis: Resurgent and Emerging Infectious Diseases* (1st Ed.). Eds. I Bastian and F Portaels. Dordrecht/Boston/London: Kluwer Academic Publishers: 175-190, 2000.
34. Iseman MD. A Catanzaro and CL Daley, Guest Editors. Medical Management of Pulmonary Disease Caused by *Mycobacterium avium* Complex. *Clinics in Chest Medicine*. Philadelphia: W.B. Saunders Company. 23(3):633-641, 2002.
35. Iseman MD and DeGroot M. *Environmental Mycobacterial (EM) Infections*. In: *Infectious Diseases*. 3rd Edition. Eds. SL Gorbach, JG Bartlett, and NR Blacklow. Philadelphia: Lippincott Williams and Wilkins, 2003.
36. Iseman MD. Tuberculosis. In: *Cecil Textbook of Medicine (22nd Ed.)*. Ed. L Goldman and JC Bennett. Philadelphia: W.B. Saunders Company, In press.

B. Other Publications:

Invited Manuscripts and Reviews:

1. Iseman MD: Flexible fiberoptic bronchoscopy. *Resident & Physicians* 52-57, February, 1973.
2. Iseman MD and Sbarbaro JA: Progress toward the containment of tuberculosis (an invited review). *Public Health Reviews - Volume III* (3 & 4):249, 1978.

3. Iseman MD: Containment of tuberculosis--preventive therapy with isoniazid and contact investigation. *Chest* 76(suppl.):801s-804s, 1979.
4. Iseman MD: Tuberculosis--far from eradicated. *Consultant* 157-165, December, 1980.
5. Iseman MD: Short Course Chemotherapy of Tuberculosis: the Harsh Realities. *Seminars in Respiratory Infections* 1(4):213-219, 1986.
6. Iseman MD. Drug Therapy: Treatment of multidrug-resistant tuberculosis. *N Engl J Med* 329(11):784-791, 1993.
7. Simone P, and Iseman M. Drug resistant tuberculosis: a deadly--and growing--danger. *J Respir Dis* 13:960-971, 1992.
8. Iseman MD. *M. avium* complex: An emerging respiratory pathogen. *J Respir Dis* 16(11):950-962, 1995.
9. Iseman, MD. Treatment and implications of multidrug-resistant tuberculosis for the 21st Century. *Chemotherapy* 45(suppl 2):34-40, 1999.
10. Iseman, MD. Management of Multidrug-resistant Tuberculosis. *Chemotherapy* 45(suppl 2):3-11, 1999.
11. Iseman, MD. Treatment and implications of multidrug-resistant tuberculosis for the 21st Century. *Chemotherapy* 45(suppl 2):34-40, 1999.
12. Iseman, MD. Summary: Update treatment of multidrug-resistant tuberculosis. *Chemotherapy* 45(suppl 2):404-45, 1999.
13. Hines SE with Cook JL, Iseman MD, Jones TF, Schaffner W. Renewed efforts toward TB control. *Patient Care* 35:4:37-51, 2001.
14. Iseman M. Twenty-first century tuberculosis in the United States: epidemiology and prevention [Perspectives, Contemporary Topics]. *MD Consult Respiratory & Critical Care Medicine*. January 30, 2003.

Letters to Editor

1. Iseman MD: Infection with *Mycobacterium avium* in monkeys. *American Review of Respiratory Disease* 108:713, 1973.
2. Moulding T, Iseman MD, Sbarbaro J: Preventing isoniazid hepatotoxicity. *Annals of Internal Medicine* 85:398, 1976.

3. Iseman MD: Clinically-derived mycobacterial classifications. *Chest* 85(4):714-715, 1984.
4. Iseman MD and Haynes Brevard J: Blood gas derangements in pulmonary embolism. *Chest* 88:155, 1985.
5. Iseman MD and Sbarbaro JA: Tuberculoid bacilli and tuberculoidosis. *Chest* 88:316-317, 1985.
5. Sbarbaro JA and Iseman MD: Baby needs a new pair of shoes. *Chest* 90:754-755, 1986.
7. Iseman MD: Tuberculosis in the elderly: treating the "White Plague" (an invited manuscript). *Geriatrics* 90-107, 1980.
8. Sbarbaro JA and Iseman MD: Prophylactic treatment of tuberculosis. *Comprehensive Therapy* 7:14-19, 1981.
7. Iseman MD: Tuberculosis prophylaxis during corticosteroid therapy. *The Journal of the American Medical Association* (Questions and Answers) 258(2):263-264, 1987.
8. Iseman MD: Corticosteroids, "conventional wisdom," and Reactivation of TB. *The Journal of Respiratory Disease* 9(7):9-10, 1988.
9. Heifets LB and Iseman MD: Choice of antimicrobial agents for *M. avium* disease based on quantitative tests of drug susceptibility. *The New England Journal of Medicine* 323(6):419-420, 1990.
10. Iseman MD and Sbarbaro JA: Compliance and tuberculosis treatment. *The Lancet* 337(June 29):1609, 1991.
11. Berning SE, Huitt GA, Iseman MD, and Peloquin CA. Malabsorption of antituberculosis medications by a patient with AIDS. *N Engl J Med* 327:1817-1818, 1992.
12. Iseman MD. That's no lady. *Chest* 109:1411, 1996.
13. Iseman MD. That's no lady revisited. Response. *Chest* 111:254-255, 1997.
14. Peloquin CA, Berning SE, Huitt GA, Iseman MD. Levofloxacin for drug-resistant *Mycobacterium tuberculosis*. *Ann Pharmacotherapy* 32:268-269, 1998.

Editorials

1. Iseman MD: Routine--a practice to be abjured. *Chest* 76:120, 1979.

2. Iseman MD: Modern tuberculosis chemotherapy: good news, bad news. *Chest* 82:396-397, 1982.
3. Iseman MD: Tuberculosis in the elderly: the grey plague. *The Journal of the American Geriatrics Society* 33(7):517, 1985.
4. Iseman M: Tailoring a time-bomb. *American Review of Respiratory Disease* 132:735-736, 1985.
5. Iseman MD: A Darwinian Dilemma. *American Review of Respiratory Disease* 135(5):990, 1987.
6. Iseman MD: Is standard chemotherapy adequate in tuberculosis patients infected with the HIV? *American Review of Respiratory Disease* 136(6):1326, 1987.
7. Iseman MD: Synergism: The Rosetta Stone for *M. avium* complex chemotherapy? *American Review of Respiratory Disease* 138:767-768, 1988.
8. Iseman MD and Miller B: If a tree falls in the middle of the forest. Isoniazid and Hepatitis. *American Review of Respiratory Disease* 140:575-576, 1989.
9. Iseman MD: Less is more: short-course preventive therapy of tuberculosis. *American Review of Respiratory Disease* 140:1187, 1989.
10. Heifets LB and Iseman MD: Individualized therapy versus standard regimens in the treatment of *Mycobacterium avium* infections. *American Review of Respiratory Disease* 144:1-2, 1991.
11. Iseman MD and Sbarbaro JA: Short-course chemotherapy of tuberculosis: Hail Britannia (and friends)! *American Review of Respiratory Disease* 143:697-698, 1991.
12. Iseman MD. A Leap of Faith. What can we do to curtail intrainstitutional transmission of tuberculosis? *Annals of Internal Medicine* 117:251-253, 1992.
13. Iseman MD, Cohn DL, and Sbarbaro JA. Directly observed treatment of tuberculosis.--We can't afford not to try it. Sounding Board. *N Engl J Med* 328(8):576-578, 1993.
14. Iseman MD and Starke J. Immigrants and tuberculosis. *N Engl J Med* 332(16):1094-1095, 1995.
15. Iseman MD. The passage of a century and the birth of a new journal. *Int J Tuberc Lung Dis* 1(1):1, 1997.

16. Iseman MD. Better means for the diagnosis of tuberculosis: 'in the meantime...' *Int J Tuberc Lung Dis* 1(1):2, 1997.
17. Sbarbaro JA and Iseman MD. "Koch's Lymph" 107 years later—an oldie but not a goldie. *Clin Infect Dis* 25:664-665, 1997.
18. Iseman MD. MDR-TB and the Developing World—A Problem No longer to be Ignored: WHO Announces "DOTS Plus" Strategy. *Int J Tuberc Lung Dis* 2(11): 867, 1998.
19. Iseman MD. Leap-frogging technology into the next century: Better diagnostic tests for TB. *Int J Tuberc Lung Dis* 2(10):777, 1998.
20. Iseman MD. Tuberculosis chemotherapy: Do it right the first time. *Southern Medical Journal* 92(4): 438-439, 1999.
21. Iseman MD. Extensively drug-resistant Mycobacterium tuberculosis: Charles Darwin would understand. *Clin Infect Dis*. 2007 Dec 1;45(11):1415-6.
22. Iseman MD, Fischer A. Tumor necrosis factor-alpha at the intersection of mycobacterial immunity and pathogenesis: an important new address in medicine. *Clin Infect Dis*. 2008 Jun 1;46(11):1741-2.

Guidelines/Position Statements

1. Guidelines for investigation and management of tuberculosis contacts. Iseman MD (Chairman), Bentz R, Locks M, Ostrow J, and Sewell E. A statement by an ad hoc committee. *American Review of Respiratory Disease* 114:459, 1976.
2. Treatment of alcoholic tuberculosis patients. Edsel J (Chairman), Awe R, Bunyan S, Hackney R, Iseman MD, Reagan P. A statement by an ad hoc committee. *American Review of Respiratory Disease* 116:559, 1977.
3. Toward eradication--a contemporary tuberculosis control strategy. Reichman LB (Chairman), Epler GR, Hopewell PC, Iseman MD, et al. Statement by Program Committee of the Scientific Assembly on Tuberculosis and the Tuberculosis Control Division of the Centers for Disease Control. *American Review of Respiratory Disease* 118:641-644, 1978.
4. Guidelines for short-course tuberculosis chemotherapy. Iseman MD (Chairman), Albert R, Farer L, Locks M, Raleigh J, Sutton F. Statement by an ad hoc committee of the Scientific Assembly on Tuberculosis of the American Thoracic Society and the Tuberculosis Control Division of the Centers for Disease Control. *American Review of Respiratory Disease* 121:611, 1980.

5. National American College of Chest Physicians Conference on Tuberculosis. Iseman MD and Sbarbaro JA, Guest Editors. *Chest* 87 (2, Suppl.):115s-149s, 1985.
6. Iseman MD: Disease due to *Mycobacterium avium-intracellulare*. *Chest* 87 (2, Suppl.):139s-149s, 1985.
7. Crofton J, Chaulet P, Maher D, Grosset J, Harris W, Horne, Iseman M, Watt B. Guidelines for the management of drug-resistant tuberculosis. *World Health Organization*: Geneva, Switzerland, 1997.
8. Targeted Tuberculin Testing and Treatment of Latent Tuberculosis Infection. American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America: treatment of tuberculosis. *Am J Respir Crit Care Med* 161(4, Suppl.):221s-247s, 2000.
9. Blumberg, H. M., W. J. Burman, et al. American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America: treatment of tuberculosis. *Am J Respir Crit Care Med* 167(4): 603-62, 2003.
10. Griffith DE, Aksamit T, Brown-Elliott BA, Catanzaro A, Daley C, Gordin F, Holland SM, Horsburgh R, Huitt G, Iademarco MF, Iseman M, Olivier K, Ruoss S, von Reyn CF, Wallace RJ Jr, Winthrop K; ATS Mycobacterial Diseases Subcommittee; American Thoracic Society; Infectious Disease Society of America. An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases. *Am J Respir Crit Care Med*. 2007 Feb 15;175(4):367-416.

Abstracts

1. Madsen LA, Carbajal J, Cook JL, and Iseman MD. Low incidence of nosocomial infection of health care workers on a tuberculosis ward equipped with ultraviolet germicidal irradiation. Presented at the Annual Meeting, American Thoracic Society, May 1994.
2. Chan ED, Iseman MD. Hypothesis: Prior infection with *Histoplasma capsulatum* predisposes to pulmonary *Mycobacterium avium* complex. American Thoracic Society Annual Meeting, May 1996. *Am J Respir and Crit Care Med* 153:A329, 1996.
3. Berning SE, Peloquin CA, Iseman MD. Clarithromycin and 14-hydroxy clarithromycin serum concentrations with or without rifampin in patients with mycobacterial infections. Presented at annual meeting, American Thoracic Society, May 16-21. 1997, San Francisco, California.

4. Berning SE, Peloquin CA, Iseman MD. Serum Concentration Monitoring of Cycloserine, Ofloxacin & Ethionamide in Patients with Mycobacterial Disease. Presented at the Conference on Global Lung Health and Annual Meeting, International Union Against Tuberculosis and Lung Disease, October 1-4, 1997, Paris, France.
5. GA Huitt, LA Powell, MD Iseman. Cystic fibrosis and α 1-antitrypsin deficiencies in relation to adult NTMsl disease. Presented at the annual meeting, American Thoracic Society, April 24-29, 1998, Chicago, Illinois.
6. Iseman MD. Tuberculosis-still the #1 killer in infectious diseases. International Journal of Clinical Practice S115: 78-87 December 2000.
7. ED Chan, V Laurel, JF Chan, ML Hyunh, M Goble, MD Iseman. Retrospective analysis of 208 patients with MDR-TB: Comparison to 171 patients from 1973 to 1983. Am J Respir and Crit Care Med 163, A497, 2002.
8. Kaminska, AM, Huitt, GA, Fulton, KE, Worthen, GS, Iseman, MD, Chan, E. Prevalence of alpha-1-antitrypsin (AAT) mutations in 100 bronchiectatic patients with rapid-growing mycobacterial (RGM) infections. Am J Respir and Crit Care Med 167, A708, 2003.